Advertisement

Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyond

Published:January 23, 2016DOI:https://doi.org/10.1016/j.ygyno.2016.01.019

      Highlights

      • Understanding causes of hereditary risk of cancer in women
      • Reviewing screening, surgical, and chemoprevention options for high-risk women
      • Highlighting new genes and multi-gene panel tests for hereditary cancer risk

      Abstract

      Obstetrician/gynecologists and gynecologic oncologists serve an integral role in the care of women at increased hereditary risk of cancer. Their contribution includes initial identification of high risk patients, screening procedures like bimanual exam, trans-vaginal ultrasound and endometrial biopsy, prophylaxis via TAH and/or BSO, and chemoprevention. Further, gynecologists also serve a central role in the management of the secondary repercussions of efforts to mitigate increased cancer risks, including vasomotor symptoms, sexual function, bone health, cardiovascular disease, and mental health. The past several years has seen multiple new high and moderate penetrance genes introduced into the clinical care of women at increased risk of gynecologic malignancy. Awareness of these new genes and the availability of new multi-gene panel tests is critical for providers on the front-line of women's health.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Daly M.B.
        • Pilarski R.
        • Axilbund J.E.
        • Buys S.S.
        • Crawford B.
        • Friedman S.
        • et al.
        National comprehensive cancer network.
        J. Natl. Compr. Cancer Netw. 2014; 12: 1326-1338
        • Moyer V.A.
        Force USPST. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.
        Ann. Intern. Med. 2014; 160: 271-281
        • Nassef S.
        Knowledge, Attitudes, and Utilization of BRCA Testing among Obstetricians and Gynecologists: UT Health Science Center at Houston.
        2012
        • Ford D.
        • Easton D.F.
        • Bishop D.T.
        • Narod S.A.
        • Goldgar D.E.
        Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
        Lancet. 1994; 343: 692-695
        • Breast Cancer Linkage C
        Cancer risks in BRCA2 mutation carriers.
        J. Natl. Cancer Inst. 1999; 91: 1310-1316
        • Jasperson K.W.
        • Tuohy T.M.
        • Neklason D.W.
        • Burt R.W.
        Hereditary and familial colon cancer.
        Gastroenterology. 2010; 138: 2044-2058
        • Provenzale D.
        • Jasperson K.
        • Ahnen D.J.
        • Aslanian H.
        • Bray T.
        • Cannon J.A.
        • et al.
        Colorectal cancer screening, version 1.2015.
        J. Natl. Compr. Cancer Netw. 2015; 13: 959-968
        • Lynch H.T.
        • Krush A.J.
        Carcinoma of the breast and ovary in three families.
        Surg. Gynecol. Obstet. 1971; 133: 644-648
        • Lynch H.T.
        • Krush A.J.
        Heredity and adenocarcinoma of the colon.
        Gastroenterology. 1967; 53: 517-527
        • Aarnio M.
        • Sankila R.
        • Pukkala E.
        • Salovaara R.
        • Aaltonen L.A.
        • de la Chapelle A.
        • et al.
        Cancer risk in mutation carriers of DNA-mismatch-repair genes.
        Int. J. Cancer. 1999; 81: 214-218
        • Ramus S.J.
        • Gayther S.A.
        The contribution of BRCA1 and BRCA2 to ovarian cancer.
        Mol. Oncol. 2009; 3: 138-150
        • Antoniou A.
        • Pharoah P.D.
        • Narod S.
        • Risch H.A.
        • Eyfjord J.E.
        • Hopper J.L.
        • et al.
        Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies.
        Am. J. Hum. Genet. 2003; 72: 1117-1130
        • Goodenberger M.L.
        • Thomas B.C.
        • Riegert-Johnson D.
        • Boland C.R.
        • Plon S.E.
        • Clendenning M.
        • et al.
        PMS2 monoallelic mutation carriers: the known unknown.
        Genet. Med. 2015;
        • Pal T.
        • Permuth-Wey J.
        • Betts J.A.
        • Krischer J.P.
        • Fiorica J.
        • Arango H.
        • et al.
        BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
        Cancer Am. Cancer Soc. 2005; 104: 2807-2816
        • Barrow E.
        • Robinson L.
        • Alduaij W.
        • Shenton A.
        • Clancy T.
        • Lalloo F.
        • et al.
        Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations.
        Clin. Genet. 2009; 75: 141-149
        • Walsh T.
        • Casadei S.
        • Lee M.K.
        • Pennil C.C.
        • Nord A.S.
        • Thornton A.M.
        • et al.
        Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
        Proc. Natl. Acad. Sci. U. S. A. 2011; 108: 18032-18037
        • Lu K.H.
        • Dinh M.
        • Kohlmann W.
        • Watson P.
        • Green J.
        • Syngal S.
        • et al.
        Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome.
        Obstet. Gynecol. 2005; 105: 569-574
        • Leenen C.H.
        • van Lier M.G.
        • van Doorn H.C.
        • van Leerdam M.E.
        • Kooi S.G.
        • de Waard J.
        • et al.
        Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤ 70 years.
        Gynecol. Oncol. 2012; 125: 414-420
        • Young R.H.
        • Welch W.R.
        • Dickersin G.R.
        • Scully R.E.
        Ovarian sex cord tumor with annular tubules: review of 74 cases including 27 with Peutz–Jeghers syndrome and four with adenoma malignum of the cervix.
        Cancer Am. Cancer Soc. 1982; 50: 1384-1402
        • Tan M.H.
        • Mester J.L.
        • Ngeow J.
        • Rybicki L.A.
        • Orloff M.S.
        • Eng C.
        Lifetime cancer risks in individuals with germline PTEN mutations.
        Clin. Cancer Res. 2012; 18: 400-407
        • Toro J.R.
        • Nickerson M.L.
        • Wei M.H.
        • Warren M.B.
        • Glenn G.M.
        • Turner M.L.
        • et al.
        Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America.
        Am. J. Hum. Genet. 2003; 73: 95-106
        • Kamihara J.
        • Rana H.Q.
        • Garber J.E.
        Germline TP53 mutations and the changing landscape of Li–Fraumeni syndrome.
        Hum. Mutat. 2014; 35: 654-662
        • Palles C.
        • Cazier J.B.
        • Howarth K.M.
        • Domingo E.
        • Jones A.M.
        • Broderick P.
        • et al.
        Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas.
        Nat. Genet. 2013; 45: 136-144
        • Cancer Genome Atlas Research N
        • Kandoth C.
        • Schultz N.
        • Cherniack A.D.
        • Akbani R.
        • Liu Y.
        • et al.
        Integrated genomic characterization of endometrial carcinoma.
        Nature. 2013; 497: 67-73
        • Hampel H.
        • Frankel W.
        • Panescu J.
        • Lockman J.
        • Sotamaa K.
        • Fix D.
        • et al.
        Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients.
        Cancer Res. 2006; 66: 7810-7817
        • Sopik V.
        • Akbari M.R.
        • Narod S.A.
        Genetic testing for RAD51C mutations: in the clinic and community.
        Clin. Genet. 2014;
        • Meindl A.
        • Hellebrand H.
        • Wiek C.
        • Erven V.
        • Wappenschmidt B.
        • Niederacher D.
        • et al.
        Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.
        Nat. Genet. 2010; 42: 410-414
        • Heikkinen K.
        • Karppinen S.M.
        • Soini Y.
        • Makinen M.
        • Winqvist R.
        Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility.
        J. Med. Genet. 2003; 40e131
        • Moyer V.A.
        Force* USPST. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement.
        Ann. Intern. Med. 2012; 157: 900-904
        • Buys S.S.
        • Partridge E.
        • Black A.
        • Johnson C.C.
        • Lamerato L.
        • Isaacs C.
        • et al.
        Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.
        J. Am. Med. Assoc. 2011; 305: 2295-2303
        • King M.C.
        • Marks J.H.
        • Mandell J.B.
        • Grp N.Y.B.C.S.
        Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
        Science. 2003; 302: 643-646
        • Rebbeck T.R.
        • Lynch H.T.
        • Neuhausen S.L.
        • Narod S.A.
        • Van't Veer L.
        • Garber J.E.
        • et al.
        Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
        N. Engl. J. Med. 2002; 346: 1616-1622
        • Finch A.
        • Beiner M.
        • Lubinski J.
        • Lynch H.T.
        • Moller P.
        • Rosen B.
        • et al.
        Salpingo–oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation.
        J. Am. Med. Assoc. 2006; 296: 185-192
        • Domchek S.M.
        • Friebel T.M.
        • Singer C.F.
        • Evans D.G.
        • Lynch H.T.
        • Isaacs C.
        • et al.
        Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
        J. Am. Med. Assoc. 2010; 304: 967-975
        • Narod S.A.
        • Risch H.
        • Moslehi R.
        • Dorum A.
        • Neuhausen S.
        • Olsson H.
        • et al.
        Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group.
        N. Engl. J. Med. 1998; 339: 424-428
        • Narod S.A.
        • Dube M.P.
        • Klijn J.
        • Lubinski J.
        • Lynch H.T.
        • Ghadirian P.
        • et al.
        Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
        J. Natl. Cancer Inst. 2002; 94: 1773-1779
        • Brohet R.M.
        • Goldgar D.E.
        • Easton D.F.
        • Antoniou A.C.
        • Andrieu N.
        • Chang-Claude J.
        • et al.
        Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group.
        J. Clin. Oncol. 2007; 25: 3831-3836
        • Schmeler K.M.
        • Lynch H.T.
        • Chen L.M.
        • Munsell M.F.
        • Soliman P.T.
        • Clark M.B.
        • et al.
        Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome.
        N. Engl. J. Med. 2006; 354: 261-269
        • Collaborative Group on Epidemiological Studies on Endometrial C
        Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies.
        Lancet Oncol. 2015; 16: 1061-1070
        • Dashti S.G.
        • Chau R.
        • Ouakrim D.A.
        • Buchanan D.D.
        • Clendenning M.
        • Young J.P.
        • et al.
        Female hormonal factors and the risk of endometrial cancer in Lynch syndrome.
        J. Am. Med. Assoc. 2015; 314: 61-71
        • Burn J.
        • Gerdes A.M.
        • Macrae F.
        • Mecklin J.P.
        • Moeslein G.
        • Olschwang S.
        • et al.
        Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.
        Lancet. 2011; 378: 2081-2087
        • Oktay K.
        • Kim J.Y.
        • Barad D.
        • Babayev S.N.
        Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks.
        J. Clin. Oncol. 2010; 28: 240-244
        • Lin W.T.
        • Beattie M.
        • Chen L.M.
        • Oktay K.
        • Crawford S.L.
        • Gold E.B.
        • et al.
        Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in Northern California.
        Cancer Am. Cancer Soc. 2013; 119: 1652-1659
        • Lammens C.
        • Bleiker E.
        • Aaronson N.
        • Vriends A.
        • Ausems M.
        • Jansweijer M.
        • et al.
        Attitude towards pre-implantation genetic diagnosis for hereditary cancer.
        Familial Cancer. 2009; 8: 457-464
        • Bradbury A.R.
        • Ibe C.N.
        • Dignam J.J.
        • Cummings S.A.
        • Verp M.
        • White M.
        • et al.
        Uptake and timing of bilateral prophylactic salpingo–oophorectomy among BRCA1 and BRCA2 mutation carriers.
        Genet. Med. 2008; 10: 161-166
        • Madalinska J.B.
        • van Beurden M.
        • Bleiker E.M.A.
        • Valdimarsdottir H.B.
        • Lubsen-Brandsma L.
        • Massuger L.F.
        • et al.
        Predictors of prophylactic bilateral salpingo–oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers.
        J. Clin. Oncol. 2007; 25: 301-307
        • Fang C.Y.
        • Cherry C.
        • Devarajan K.
        • Li T.Y.
        • Malick J.
        • Daly M.B.
        A prospective study of quality of life among women undergoing risk-reducing salpingo–oophorectomy versus gynecologic screening for ovarian cancer.
        Gynecol. Oncol. 2009; 112: 594-600
        • Finch A.
        • Metcalfe K.A.
        • Chiang J.K.
        • Elit L.
        • McLaughlin J.
        • Springate C.
        • et al.
        The impact of prophylactic salpingo–oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation.
        Gynecol. Oncol. 2011; 121: 163-168
        • Acheson L.S.
        • Zyzanski S.J.
        • Stange K.C.
        • Deptowicz A.
        • Wiesner G.L.
        Validation of a self-administered, computerized tool for collecting and displaying the family history of cancer.
        J. Clin. Oncol. 2006; 24: 5395-5402
        • Committee S.C.P.
        • Lancaster J.M.
        • Powell C.B.
        • Chen L.
        • Richardson D.L.
        Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.
        Gynecol. Oncol. 2015; 136: 3-7
        • Lu K.H.
        • Wood M.E.
        • Daniels M.
        • Burke C.
        • Ford J.
        • Kauff N.D.
        • et al.
        American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers.
        J. Clin. Oncol. 2014; 32: 833-+
        • Hampel H.
        • Frankel W.L.
        • Martin E.
        • Arnold M.
        • Khanduja K.
        • Kuebler P.
        • et al.
        Feasibility of screening for Lynch syndrome among patients with colorectal cancer.
        J. Clin. Oncol. 2008; 26: 5783-5788
        • Mvundura M.
        • Grosse S.D.
        • Hampel H.
        • Palomaki G.E.
        The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer.
        Genet. Med. 2010; 12: 93-104
      1. SGO Clinical Practice Statement: screening for Lynch Syndrome in endometrial cancer.
        • Buchanan D.D.
        • Tan Y.Y.
        • Walsh M.D.
        • Clendenning M.
        • Metcalf A.M.
        • Ferguson K.
        • et al.
        Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.
        J. Clin. Oncol. 2014; 32
        • Rybak C.
        • Hall M.J.
        Interpretation of genetic testing for Lynch syndrome in patients with putative familial colorectal cancer.
        J. Natl. Compr. Cancer Netw. 2011; 9: 1311-1320
        • Brueg A.S.
        • Djordjevic B.
        • Rajyalakshmi L.
        • Lu K.H.
        • Sun C.C.L.
        • Broaddus R.
        Cost analysis comparing universal tumor testing to clinically based criteria in the evaluation of endometrial adenocarcinomas for Lynch syndrome.
        Gynecol. Oncol. 2014; 133: 2-207
        • Barzi A.
        • Sadeghi S.
        • Kattan M.W.
        • Meropol N.J.
        Comparative effectiveness of screening strategies for Lynch syndrome.
        J. Natl. Cancer Inst. 2015; 107
        • Grosse S.D.
        • Palomaki G.E.
        • Mvundura M.
        • Hampel H.
        The cost-effectiveness of routine testing for Lynch syndrome in newly diagnosed patients with colorectal cancer in the United States: corrected estimates.
        Genet. Med. 2015; 17: 510-511
        • Hall M.J.
        Counterpoint: implementing population genetic screening for Lynch Syndrome among newly diagnosed colorectal cancer patients—will the ends justify the means?.
        J. Natl. Compr. Cancer Netw. 2010; 8: 606-611
        • Heald B.
        • Plesec T.
        • Liu X.
        • Pai R.
        • Patil D.
        • Moline J.
        • et al.
        Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing Lynch syndrome in a large academic medical center.
        J. Clin. Oncol. 2013; 31: 1336-1340
        • Hall M.J.
        • Forman A.D.
        • Pilarski R.
        • Wiesner G.
        • Giri V.N.
        Gene panel testing for inherited cancer risk.
        J. Natl. Compr. Cancer Netw. 2014; 12: 1339-1346
        • Yu X.C.
        • Chini C.C.S.
        • He M.
        • Mer G.
        • Chen J.J.
        The BRCT domain is a phospho-protein binding domain.
        Science. 2003; 302: 639-642
        • Domchek S.M.
        • Stopfer J.E.
        • Rebbeck T.R.
        Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers.
        J. Natl. Compr. Cancer Netw. 2006; 4: 177-182
        • Cui Y.
        • Zong H.
        • Yan H.
        • Li N.
        • Zhang Y.
        The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis.
        J. Sex. Med. 2014; 11: 487-497
        • Kingsberg S.A.
        • Woodard T.
        Female sexual dysfunction focus on low desire.
        Obstet. Gynecol. 2015; 125: 477-486
        • Garcia C.
        • Lyon L.
        • Conell C.
        • Littell R.D.
        • Powell C.B.
        Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo–oophorectomy.
        Gynecol. Oncol. 2015; 138: 723-726
        • Arts-de Jong M.
        • Harmsen M.G.
        • Hoogerbrugge N.
        • Massuger L.F.
        • Hermens R.P.
        • de Hullu J.A.
        Risk-reducing salpingectomy with delayed oophorectomy in BRCA1/2 mutation carriers: patients' and professionals' perspectives.
        Gynecol. Oncol. 2015; 136: 305-310
        • Colditz G.A.
        Hormones and breast cancer: evidence and implications for consideration of risks and benefits of hormone replacement therapy.
        J. Women's Health. 1999; 8: 347-357
        • Michelsen T.M.
        • Dorum A.
        • Trope C.G.
        • Fossa S.D.
        • Dahl A.A.
        Fatigue and quality of life after risk-reducing salpingo–oophorectomy in women at increased risk for hereditary breast–ovarian cancer.
        Int. J. Gynecol. Cancer. 2009; 19: 1029-1036